{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:08:18Z","timestamp":1794607698497,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC). However, the clinical benefit of cetuximab as an EGFR-targeting drug is still controversial, partially due to the lack of effective means to identify suitable patients. This study aimed to investigate the potential of radiolabeled cetuximab as a non-invasive tool to predict cetuximab accumulation in NSCLC tumor xenografts with varying EGFR expression levels.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The NSCLC tumors in model mice were subjected to in vivo biodistribution study and positron emission tomography (PET) imaging 48\u2009h after injection of either <jats:sup>111<\/jats:sup>In- or <jats:sup>64<\/jats:sup>Cu-labeled cetuximab. The EGFR expression levels of NSCLC tumors were determined by ex vivo immunoblotting.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that tumors with high EGFR expression had significantly higher [<jats:sup>111<\/jats:sup>In]In-DOTA-cetuximab accumulation than tumors with moderate to low EGFR expression (<jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.05). Strong correlations were found between [<jats:sup>111<\/jats:sup>In]In-DOTA-cetuximab tumor uptake and EGFR expression level (<jats:italic>r<\/jats:italic>\u00a0=\u20090.893), and between [<jats:sup>64<\/jats:sup>Cu]Cu-DOTA-cetuximab tumor uptake with EGFR expression level <jats:italic>(<\/jats:italic>r\u2009=\u20090.915). PET imaging with [<jats:sup>64<\/jats:sup>Cu]Cu-DOTA-cetuximab allowed clear visualization of tumors.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings suggest that this immuno-PET imaging can be clinically translated as a tool to predict cetuximab accumulation in NSCLC cancer patients prior to cetuximab therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6238-4","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T17:06:33Z","timestamp":1572023193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Aiko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arifudin","family":"Achmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-7397","authenticated-orcid":false,"given":"Hirofumi","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusri Dwi","family":"Heryanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ratianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdene","family":"Khongorzul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rini","family":"Shintawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Adhipatria P.","family":"Kartamihardja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Sugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"S. Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"6238_CR1","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 3rd ed. 2018;68:7\u201330."},{"key":"6238_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446.","journal-title":"Nature."},{"key":"6238_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2013.11.006","volume":"83","author":"J-L Pujol","year":"2014","unstructured":"Pujol J-L, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014;83:211\u20138.","journal-title":"Lung Cancer"},{"key":"6238_CR4","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-13-3385","volume":"20","author":"C Amendt","year":"2014","unstructured":"Amendt C, Staub E, Friese-Hamim M, Storkel S, Stroh C. Association of EGFR expression level and Cetuximab activity in patient-derived Xenograft models of human non-small cell lung Cancer. Clin Cancer Res. 2014;20:4478\u201387.","journal-title":"Clin Cancer Res"},{"key":"6238_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1470-2045(17)30694-0","volume":"19","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, KO MD, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018;19:101\u201314.","journal-title":"Lancet Oncol"},{"key":"6238_CR6","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non\u2013small-cell lung Cancer. N Engl J Med. 2017;376:2109\u201321.","journal-title":"N Engl J Med"},{"key":"6238_CR7","doi-asserted-by":"crossref","first-page":"100863","DOI":"10.18632\/oncotarget.19809","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, et al. Challenges and future of biomarker tests in the era of precision oncology: can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017;8:100863\u201398.","journal-title":"Oncotarget."},{"key":"6238_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1634\/theoncologist.12-12-1379","volume":"12","author":"GAMS van Dongen","year":"2007","unstructured":"van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379\u201389.","journal-title":"Oncologist"},{"key":"6238_CR9","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"key":"6238_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","volume":"5","author":"H Kurihara","year":"2015","unstructured":"Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, et al. 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5:8.","journal-title":"EJNMMI Res"},{"key":"6238_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.2967\/jnumed.108.052316","volume":"49","author":"M Eiblmaier","year":"2008","unstructured":"Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-Cetuximab in 5 cervical Cancer cell lines. J Nucl Med. 2008;49:1472\u20139.","journal-title":"J Nucl Med"},{"key":"6238_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1349-7006.2011.02166.x","volume":"103","author":"A Achmad","year":"2011","unstructured":"Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, et al. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci. 2011;103:600\u20135.","journal-title":"Cancer Sci"},{"key":"6238_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-006-0361-6","volume":"34","author":"W Cai","year":"2007","unstructured":"Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6238_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2967\/jnumed.108.054312","volume":"50","author":"HJWL Aerts","year":"2008","unstructured":"Aerts HJWL, Dubois L, Perk L, Vermaelen P, van Dongen GAMS, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled Cetuximab uptake assessed with PET. J Nucl Med. 2008;50:123\u201331.","journal-title":"J Nucl Med"},{"key":"6238_CR15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1158\/1078-0432.CCR-09-2495","volume":"16","author":"G Niu","year":"2010","unstructured":"Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, et al. Cetuximab-based immunotherapy and Radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010;16:2095\u2013105.","journal-title":"Clin Cancer Res"},{"key":"6238_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/cbr.2013.1562","volume":"29","author":"H Hanaoka","year":"2014","unstructured":"Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, et al. Fractionated Radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother Radiopharm. 2014;29:70\u20136.","journal-title":"Cancer Biother Radiopharm"},{"key":"6238_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/cbr.2007.0444","volume":"23","author":"W Ping Li","year":"2008","unstructured":"Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23:158\u201371.","journal-title":"Cancer Biother Radiopharm"},{"key":"6238_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tips.2007.10.015","volume":"29","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt M, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:1\u20135.","journal-title":"Trends Pharmacol Sci"},{"key":"6238_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"Antibody tumor penetration","year":"2008","unstructured":"Antibody tumor penetration. Transport opposed by systemic and antigen-mediated clearance. Adv Drug Delivery Rev. 2008;60:1421\u201334.","journal-title":"Adv Drug Delivery Rev"},{"key":"6238_CR20","doi-asserted-by":"publisher","first-page":"e81157","DOI":"10.1371\/journal.pone.0081157","volume":"8","author":"S Stapleton","year":"2013","unstructured":"Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. Chuu C-P, editor. PLoS One. 2013;8:e81157\u201310.","journal-title":"PLoS One"},{"key":"6238_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"6238_CR22","doi-asserted-by":"crossref","unstructured":"Nayak TK, Regino CAS, Wong KJ, Milenic DE, Garmestani K, Baidoo KE et al. PET imaging of HER1-expressing xenografts in mice with 86Y-CHXA\u201d-DTPA-cetuximab. Eur J Nucl Med Mol Imaging; 2010;37:1368\u20131376.","DOI":"10.1007\/s00259-009-1370-z"},{"key":"6238_CR23","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-05-4010","volume":"66","author":"JJL van Bueren","year":"2006","unstructured":"van Bueren JJL, Bleeker WK, B\u00f8gh HO, Houtkamp M, Schuurman J, van de Winkel JGJ, et al. Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action. Cancer Res. 2006;66:7630\u20138.","journal-title":"Cancer Res"},{"key":"6238_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/ijc.25727","volume":"129","author":"BA Hoeben","year":"2011","unstructured":"Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, et al. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer. 2011;129:870\u20138.","journal-title":"Int J Cancer"},{"key":"6238_CR25","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","volume":"54","author":"K Tamura","year":"2013","unstructured":"Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-Trastuzumab PET imaging in patients with HER2-positive breast Cancer. J Nucl Med. 2013;54:1869\u201375.","journal-title":"J Nucl Med"},{"key":"6238_CR26","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","volume":"6","author":"CW Menke-van der Houven van Oordt","year":"2015","unstructured":"Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384\u201393.","journal-title":"Oncotarget"},{"key":"6238_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","volume":"13","author":"R Pirker","year":"2012","unstructured":"Pirker R, Pereira JR, Pawel von J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33\u201342.","journal-title":"Lancet Oncol."},{"key":"6238_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1200\/JCO.2009.25.2890","volume":"28","author":"S Khambata-Ford","year":"2010","unstructured":"Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu L-A, Horak CE, et al. Analysis of potential predictive markers of Cetuximab benefit in BMS099, a phase III study of Cetuximab and first-line Taxane\/carboplatin in advanced non\u2013small-cell lung Cancer. J Clin Oncol. 2010;28:918\u201327.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6238-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T23:05:40Z","timestamp":1603407940000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6238-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6238"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6238-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal studies were performed in accordance with our institutional guidelines and were approved by the Local Animal Care Committee of Gunma University (approval number: 17\u2013035).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Note applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1000"}}